Clinical Trial Update: Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of sunitinib and gemcitabine in sarcomatoid or poor-risk metastatic renal cell carcinoma has completed. Results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma
• Sarcomatoid Renal Cell Carcinoma

Drugs mentioned

• Gemzar (gemcitabine)
• Sutent (sunitinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Renal Cell Carcinoma, Neoplasm Metastases | Phase 2 | Status: COMPLETED | Results posted: 2015-04-03